BMY 42393Alternative Names: BMY 45491; BMY 45778
Latest Information Update: 26 Jul 1994
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperlipidaemics; Antiplatelets
- Mechanism of Action Prostacyclin agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hyperlipidaemia